Skip to main content

Advertisement

Table 4 Resource use by predictive biomarker testing status in Italy, Spain, Germany, and Australia

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

  Italy
(N = 174)
Spain
(N = 202)
Germany
(N = 139)
Australia
(N = 208)
EGFR/ALK tested Not tested EGFR/ALK tested Not tested EGFR/ALK tested Not tested EGFR/ALK tested Not tested
Pos Neg/Unk Pos Neg/Unk Pos Neg/Unk Pos Neg/Unk
First-line therapy N = 22 N = 66 N = 86 N = 24 N = 121 N = 57 N = 21 N = 55 N = 63 N = 31 N = 95 N = 82
No. inpatient staysa 13 26 36 13 72 28 17 49 74 40 209 78
 Hospital 13 (100) 26 (100) 36 (100) 13 (100) 71 (99) 28 (100) 17 (100) 49 (100) 74 (100) 35 (88) 175 (84) 74 (95)
 Hospice 0 0 0 0 1 (1) 0 0 0 0 5 (13) 34 (16) 4 (5)
No. hospitalizationsb 13 26 36 13 71 28 15 52 85 35 177 74
 Normal ward 13 (100) 26 (100) 35 (97) 13 (100) 71 (100) 28 (100) 15 (100) 48 (92) 72 (85) 35 (100) 175 (99) 74 (100)
 ICU 0 0 1 (3) 0 0 0 0 4 (8) 13 (15) 0 2 (1) 0
No. hospitalizations with LOSc 13 25 35 13 70 28 17 49 74 35 173 73
 Mean (SD) days 4.5 (4.2) 7.8 (10.0) 5.4 (6.9) 7.5 (6.4) 8.8 (5.8) 9.1 (5.9) 13.6 (12.4) 9.7 (12.3) 7.4 (10.1) 3.5 (5.6) 4.6 (4.8) 5.2 (7.5)
 Median (range) 4 (1–14) 5 (3–50) 1 (1–26) 6 (2–27) 7 (1–28) 7 (1–26) 9 (1–32) 4 (1–32) 3 (1–32) 1 (1–33) 3 (1–27) 3 (1–48)
Outpatient visits, nd 19 63 64 21 92 32 11 25 32 29 93 73
 Mean (SD) visits 9.1 (8.4) 8.9 (8.3) 5.7 (3.8) 9.4 (9.7) 11.8 (12.8) 7.8 (7.1) 16.0 (10.7) 10.6 (9.7) 7.6 (9.7) 26.7 (30.3) 12.9 (12.4) 7.8 (6.9)
 Median (range) 8 (1–35) 6 (1–34) 5 (1–17) 6 (1–42) 9 (1–58) 6 (1–23) 13 (2–31) 7 (1–41) 3 (1–33) 21 (1–105) 9 (1–57) 6 (1–33)
No. outpatient visits 173 562 367 198 1089 250 176 266 242 774 1203 569
Second-line therapy N = 14 N = 41 N = 46 N = 14 N = 62 N = 20 N = 14 N = 27 N = 23 N = 22 N = 66 N = 40
No. inpatient staysa 3 5 5 10 33 6 14 13 12 20 51 18
 Hospital 3 (100) 5 (100) 5 (100) 8 (80) 33 (100) 6 (100) 14 (100) 13 (100) 12 (100) 20 (100) 49 (96) 18 (100)
 Hospice 0 0 0 2 (20) 0 0 0 0 0 0 2 (4) 0
No. hospitalizationsb 3 5 5 8 33 6 14 13 12 20 49 18
 Normal ward 3 (100) 5 (100) 5 (100) 8 (100) 33 (100) 6 (100) 14 (100) 13 (100) 12 (100) 20 (100) 49 (100) 18 (100)
 ICU 0 0 0 0 0 0 0 0 0 0 0 0
No. hospitalizations with LOSc 3 5 5 8 32 6 14 13 12 20 49 18
 Mean (SD) days 8.3 (1.2) 9.8 (4.3) 3.8 (4.4) 12.3 (5.3) 10.2 (5.4) 10.0 (4.5) 10.3 (10.5) 7.0 (11.1) 8.2 (6.1) 4.7 (3.4) 5.6 (7.4) 6.3 (4.7)
 Median (range) 9 (7–9) 9 (4–15) 1 (1–11) 14 (5–17) 10 (3–19) 11 (2–15) 6 (1–32) 1 (1–32) 8 (1–19) 4 (1–9) 3 (1–44) 6 (2–21)
Outpatient visits, nd 13 34 25 9 41 12 12 13 10 18 62 22
 Mean (SD) visits 11.5 (12.6) 5.8 (5.9) 6.1 (3.8) 8.3 (4.2) 6.6 (4.8) 7.0 (3.9) 8.2 (10.4) 4.7 (4.2) 6.1 (4.4) 7.3 (5.3) 8.6 (7.1) 5.2 (4.3)
 Median (range) 6 (1–41) 3 (1–25) 6 (1–16) 7 (3–15) 6 (1–17) 8 (1–12) 4 (1–30) 2 (1–12) 7 (1–11) 6 (1–20) 6 (1–26) 4 (1–17)
No. outpatient visits 149 196 153 75 269 84 98 61 61 131 533 115
  1. aTotal number of inpatient stays, defined as one or more nights in a hospital or hospice
  2. bTotal number of hospitalizations, not including hospice stays
  3. cTotal number of hospitalizations with non-missing data regarding length of stay (LOS)
  4. dNumber of patients who had ≥1 outpatient visits
  5. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, LOS length of stay, Neg/Unk negative/unknown, No. number of, OP outpatient, Pos positive